SLX9
Ribosome biogenesis protein SLX9 homolog
Also known as: C21orf70, FAM207A, PRED56, SLX9_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9NSI2
- Gene
- SLX9
- Ensembl
- ENSG00000160256
- Chromosome
- 21
- Canonical length
- 230 aa
- Protein class
- Predicted intracellular proteins
- Subcellular location
- Nucleoplasm,Nucleoli
OverviewNCBI Gene
Predicted to be involved in maturation of SSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA). Predicted to be located in nucleolus. Predicted to be part of 90S preribosome and preribosome, small subunit precursor. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
230 residues, UniProt reviewed canonical sequence.
>Q9NSI2|SLX9
1 MGKVRGLRAR VHQAAVRPKG EAAPGPAPPA PEATPPPASA AGKDWAFINT NIFARTKIDP
61 SALVQKLELD VRSVTSVRRG EAGSSARSVP SIRRGAEAKT VLPKKEKMKL RREQWLQKIE
121 AIKLAEQKHR EERRRRATVV VGDLHPLRDA LPELLGLEAG SRRQARSRES NKPRPSELSR
181 MSAAQRQQLL EEERTRFQEL LASPAYRASP LVAIGQTLAR QMQLEDGGQLLocalizationUniProt · AlphaFold · HPA
Whether an antibody against SLX9 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.6
- Highest tissue expression
- 52 nTPM
Expression across tissuesHPA
Tissue
- heart muscle: 52 nTPM
- skeletal muscle: 43 nTPM
- blood vessel: 31 nTPM
- liver: 31 nTPM
- testis: 27 nTPM
- spleen: 24 nTPM
Single-cell type
- oocytes: 175 nCPM
- thymic myoid cells: 144 nCPM
- esophageal basal cells: 95 nCPM
- late primary spermatocytes: 91 nCPM
- esophageal suprabasal cells: 90 nCPM
- extravillous trophoblasts: 88 nCPM
Immune cell
- plasmacytoid DC: 9 nTPM
- memory B-cell: 7.8 nTPM
- naive B-cell: 5 nTPM
- non-classical monocyte: 4.7 nTPM
- NK-cell: 4.5 nTPM
- memory CD8 T-cell: 4.3 nTPM
Brain region
- cerebellum: 36 nTPM
- thalamus: 33 nTPM
- cerebral cortex: 31 nTPM
- medulla oblongata: 30 nTPM
- midbrain: 30 nTPM
- basal ganglia: 29 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.94
- gnomAD pLI
- 0.08
- DepMap mean gene effect
- -0.23
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- LSU-rRNA)
- maturation of SSU-rRNA from tricistronic rRNA transcript (SSU-rRNA
- 5.8S rRNA
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Ribosome biogenesis protein Slx9-like
- Ribosome biogenesis protein SLX9
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of SLX9 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads SLX9 as an antibody target. Whether an autoantibody or antibody against SLX9 could matter depends on whether native SLX9 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
SLX9 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label SLX9 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...